Although effective cancer therapies, including personalized medicine using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, have significantly improved the prognosis and survival of lung cancer patients [2], the 5-year survival rate of patients with metastatic lung cancer is still less than 5 % [1]. This evidence concerns the gene ALK and lung cancer.